Literature DB >> 18221302

HCV-specific T-cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance.

T A Ruys1, N M Nanlohy, C H S B van den Berg, E Hassink, M Beld, T van de Laar, S Bruisten, F Wit, A Krol, M Prins, J Lange, D van Baarle.   

Abstract

In order to understand the parameters associated with resolved hepatitis C virus (HCV)-infection, we analysed the HCV-specific T-cell responses longitudinally in 13 injecting drug-users (IDUs) with a prospectively identified acute HCV infection. Seven IDUs cleared HCV and six IDUs remained chronically infected. T-cell responses were followed in the period needed to resolve and a comparable time span in chronic carriers. Ex vivo T-cell responses were measured using interferon-gamma Elispot assays after stimulation with overlapping peptide pools spanning the complete HCV genome. CD4+ memory-T-cell responses were determined after 12-day stimulation with HCV proteins. The maximum response was compared between individuals. The T-cell responses measured directly ex vivo were weak but significantly higher in resolvers compared to chronic carriers, whereas the CD4+ memory-T-cell response was not different between resolvers and chronic carriers. However, HCV Core protein was targeted more often in chronic carriers compared to individuals resolving HCV infection. CD4+ T-cell responses predominantly targeting nonstructural proteins were associated with resolved HCV infection. Interestingly, observation of memory-T-cell responses present before the documented HCV-seroconversion suggests that reinfections in IDUs occur often. The presence of these responses however, were not predictive for the outcome of infection. However, a transition of the HCV-specific CD4+ memory-T-cell response from targeting Core to targeting nonstructural proteins during onset of infection was associated with a favourable outcome. Therefore, the specificity of the CD4+ memory-T-cell responses measured after 12-day expansion seems most predictive of resolved infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18221302     DOI: 10.1111/j.1365-2893.2007.00963.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.

Authors:  J K Flynn; G J Dore; M Hellard; B Yeung; W D Rawlinson; P A White; J M Kaldor; A R Lloyd; R A Ffrench
Journal:  J Viral Hepat       Date:  2010-07-05       Impact factor: 3.728

3.  Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort.

Authors:  Charlotte H B S van den Berg; Bart P X Grady; Janke Schinkel; Thijs van de Laar; Richard Molenkamp; Robin van Houdt; Roel A Coutinho; Debbie van Baarle; Maria Prins
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

Review 4.  The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals.

Authors:  Emma C Thomson; Jennifer A Smith; Paul Klenerman
Journal:  J Gen Virol       Date:  2011-07-20       Impact factor: 3.891

5.  HCV genotype-3a T cell immunity: specificity, function and impact of therapy.

Authors:  Isla S Humphreys; Annette von Delft; Anthony Brown; Linda Hibbert; Jane D Collier; Graham R Foster; Monira Rahman; Annabel Christian; Paul Klenerman; Eleanor Barnes
Journal:  Gut       Date:  2012-02-15       Impact factor: 23.059

6.  TH1 cytokine response to HCV peptides in Egyptian health care workers: a pilot study.

Authors:  Mona M Rafik; Alaa El-Dien M S Hosny; Khaled O Abdallah; Amal A Abbas; Rania A Abo Shady; Dina A Soliman; Khaled M Nasr El-Din Rakha; Shahira F Alfedawy
Journal:  Virol J       Date:  2013-05-11       Impact factor: 4.099

7.  Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection.

Authors:  Vicki M Fleming; Gillian Harcourt; Eleanor Barnes; Paul Klenerman
Journal:  J Gen Virol       Date:  2010-01-27       Impact factor: 3.891

8.  HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection.

Authors:  Bart P X Grady; Nening M Nanlohy; Debbie van Baarle
Journal:  Immun Ageing       Date:  2016-03-31       Impact factor: 6.400

9.  HLA Preferences for Conserved Epitopes: A Potential Mechanism for Hepatitis C Clearance.

Authors:  Xiangyu Rao; Ilka Hoof; Debbie van Baarle; Can Keşmir; Johannes Textor
Journal:  Front Immunol       Date:  2015-10-29       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.